Search fresh public links, source activity, and ready-to-use post angles for Abbv.
Fresh curated links around ABBV are collected here so marketers can spot useful updates and turn timely ideas into posts faster.
Recent items include:
Recent curated links from global sources. Generate one free draft from any story, then use SocialBu to schedule and refine your content calendar.
The pharmaceutical company hopes that another big-time acquisition will pay off.
AbbVie's immunology pivot is offsetting Humira's decline, while Pfizer trades at half the valuation despite patent risks ahead.
AbbVie has another blockbuster business emerging.
AbbVie trades cheaper but carries heavy revenue concentration; Johnson & Johnson boasts a fortress balance sheet and wider portfolio.
Eli Lilly's metabolic therapies drove 45% revenue growth, but its valuation premium demands scrutiny against AbbVie's defensive dividend appeal.
It would be hard for investors to replicate the company's return over the past decade.
Another potential blockbuster just joined AbbVie's drug portfolio.
These two high-quality dividend payers have had very different fortunes recently.
Free cash flow surged over $150M as working capital improved and ERP systems stabilized.
These companies are committed to rewarding shareholders.
The drugmaker is leaning on a better side effect profile compared to drugs from J&J, Pfizer and Regeneron as it pushes etentamig toward FDA submission.
ZEVASKYN revenue surged 31% to $11.4 million as treatment network expanded.
Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.